TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Phase 1 Terminated 9 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy of TQ05105 Tablets in patients with intermediate-risk and high-risk myelofibrosis.

Timeline

Start: 2022-08-01
Primary completion: 2025-08-12
Completion: 2025-08-12

Outcome

Outcome not reported

Stopped (Business): “This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.”

Publications

Hong M, Ding D, Zhang M, Gao S, Song L, Wu D, Lao S, Yu D, Chang C. A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study. Eur J Pharmacol. 2025 Oct 15;1005:178032. doi: 10.1016/j.ejphar.2025.178032. Epub 2025 Aug 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rovadicitinib	Small molecule	—	Oral